Literature DB >> 29296729

Therapy-related myelofibrosis does not appear to exist.

Lucia Masarova1, Gabriele Todisco2, Taghi Manshouri1, Kate J Newberry1, Jorge E Cortes1, Hagop M Kantarjian1, Zeev Estrov1, Srdan Verstovsek1.   

Abstract

There is no evidence to support the existence of therapy-related myelofibrosis.Therapy for previous malignancy has no impact on myelofibrosis prognosis.

Entities:  

Year:  2017        PMID： 29296729      PMCID： PMC5737601          DOI： 10.1182/bloodadvances.2017007369

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  11 in total

1.  Prognosis in therapy-related acute myeloid leukemia and impact of karyotype.

Authors:  Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

2.  Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.

Authors:  Lucia Masarova; Mohamad Cherry; Kate J Newberry; Zeev Estrov; Jorge E Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-09-25

3.  High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.

Authors:  Mohsen Karimi; Christer Nilsson; Marios Dimitriou; Monika Jansson; Hans Matsson; Per Unneberg; Sören Lehmann; Juha Kere; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

4.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.

Authors:  Robert R West; Amy P Hsu; Steven M Holland; Jennifer Cuellar-Rodriguez; Dennis D Hickstein
Journal:  Haematologica       Date:  2013-09-27       Impact factor: 9.941

5.  International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

Authors:  Kebede Hussein; Animesh D Pardanani; Daniel L Van Dyke; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

Review 6.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 8.  Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Gautam Borthakur; And Elihu E Estey
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

9.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.

Authors:  C Schoch; W Kern; S Schnittger; W Hiddemann; T Haferlach
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

10.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Authors:  D Caramazza; K H Begna; N Gangat; R Vaidya; S Siragusa; D L Van Dyke; C Hanson; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528
View more
  1 in total

Review 1.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.